G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

- Analyses of Data from the Randomized Phase 2 Metastatic Triple Negative Breast Cancer Trial Indicate That Prior Use of Trilaciclib with Cytotoxic Chemotherapy is Highly Correlated to Improved...

Related Keywords

San Antonio ,Texas ,United States ,American ,Raj Malik ,Research Triangle Park ,American Cancer Society ,Therapeutics Inc ,Nasdaq ,Linkedin ,Exchange Commission ,Investor Relations Corporate Communications ,Randomized Phase ,Triple Negative Breast Cancer ,Trial Indicate That Prior Use ,Highly Correlated ,Improved Long Term Survival ,Subsequent Anticancer Therapies ,Long Term Survival Also Observed ,Patients Who Received Prior Trilaciclib ,Cytotoxic Therapy ,Were Unable ,Receive Subsequent Anticancer Therapy ,Antonio Breast Cancer Symposium ,Chief Medical Officer ,Private Securities Litigation Reform Act ,Investor Relations ,Markets ,